Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Perspective Therapeutics, Inc. (CATX)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
$0.79-9.40%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CATX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund clinical milestones into late 2027 | Perspective Therapeutics aims to fund clinical milestones into late 2027. | Intact | cash and investments fall short of funding clinical milestones into late 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The thesis is on watch: recent performance is below its industry cohort, while management has made mixed progress on development, manufacturing, and funding priorities.
CATX carries a durable premium of 48% versus peers, even though it is loss-making and the value signal is also loss-making. The expectations gap is elevated, but the priced-in tag is marked unjustified and no fragility gates fired; valuation has fallen substantially in recent months, though the evidence gives no share-price figure.
Near term, the earnings picture remains uncertain: CATX has reported recent earnings beats, but its earnings surprises have been erratic and the risk rating is high. For the multi-year thesis, October’s VMT-α-NET response and disease-control results support continued development, while Phase 3 preparations remain underway for an expected 2027 start. Cash was about $237 million at June 30, 2026, with management stating it covers planned milestones and operations into late 2027; manufacturing investment is visible, but completed capacity gains are not established.
The key clinical swing factor is whether VMT-α-NET advances from promising reported results to the planned Phase 3 program. Near term, a guidance cut would be a meaningful negative, while continued weakness in the jobs report could add pressure through recession concerns. Continued earnings strength and higher guidance from sector bellwethers such as ABT, MDT, and SYK would support the sector backdrop, but would not resolve CATX’s company-specific clinical and funding risks.
Over the next 1 to 3 years, the long-term thesis rests on clinical execution and using the stated cash runway to fund planned milestones, against a high-risk, loss-making profile and a premium valuation. Evidence remains limited and mixed, so progress toward Phase 3 and future guidance are central to the multi-year view. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management focuses on reducing operating losses, which were -$28.28M in 2026-Q1. |
| Broken |
| operating losses worsen or remain stagnant below -$28M over next year |
Operating income: $-29.258M FY2026-Q4; GAAP. Published target: Operating losses improve from -$28.28M in 2026-Q1 toward less negative levels. Target period is not explicitly aligned with this observation. Aug 10, 2026-29,258,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize or grow revenue | A supporting condition in Perspective Therapeutics, Inc.'s published investment case. The stated target is Revenue decline less than -85% next year or stabilize. | Broken | revenue declines more than -85% next year | Revenue: $81,000 FY2026-Q2; GAAP. Published target: Revenue decline less than -85% next year or stabilize. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 202681,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.10 → $-1.01 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.10 | $448,699 | 7 / 7 |
| 2026-07-25 | $-1.10 | $448,699 | 7 / 7 |
| 2026-07-26 | $-1.10 | $448,699 | 7 / 7 |
| 2026-07-27 | $-1.10 | $448,699 | 7 / 7 |
| 2026-07-28 | $-1.10 | $448,699 | 7 / 7 |
| 2026-07-29 | $-1.13 | $487,540 | 6 / 11 |
| 2026-07-30 | $-1.13 | $487,540 | 6 / 11 |
| 2026-07-31 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-01 | $-1.13 | $487,540 | 6 / 11 |
| 2026-08-02 | $-1.13 | $487,540 | 6 / 11 |
| 2026-08-03 | $-1.13 | $487,540 | 6 / 11 |
| 2026-08-04 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-05 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-06 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-07 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-08 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-09 | $-1.13 | $487,540 | 6 / 11 |
| 2026-08-10 | $-1.13 | $487,540 | 6 / 11 |
| 2026-08-11 | $-1.12 | $487,540 | 6 / 11 |
| 2026-08-12 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-13 | $-1.08 | $471,500 | 7 / 10 |
| 2026-08-14 | $-1.10 | $448,699 | 7 / 7 |
| 2026-08-15 | $-1.10 | $448,699 | 8 / 7 |
| 2026-08-16 | $-1.10 | $448,699 | 7 / 8 |
| 2026-08-17 | $-1.10 | $448,699 | 7 / 8 |
| 2026-08-18 | $-1.10 | $448,699 | 7 / 8 |
| 2026-08-19 | $-1.10 | $448,699 | 7 / 8 |
| 2026-08-20 | $-1.10 | $448,699 | 8 / 8 |
| 2026-08-21 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-22 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-23 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-24 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-25 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-26 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-27 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-28 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-29 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-30 | $-1.03 | $344,848 | 9 / 9 |
| 2026-08-31 | $-1.01 | $376,198 | 9 / 9 |
| 2026-09-01 | $-1.01 | $376,198 | 8 / 9 |
| 2026-09-02 | $-1.01 | $376,198 | 8 / 9 |
| 2026-09-03 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-04 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-05 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-06 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-07 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-08 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-09 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-10 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-11 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-12 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-13 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-14 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-15 | $-1.01 | $376,198 | 8 / 8 |
| 2026-09-16 | $-1.03 | $376,198 | 8 / 8 |
| 2026-09-17 | $-1.03 | $376,198 | 8 / 8 |
| 2026-09-18 | $-1.03 | $376,198 | 8 / 8 |
| 2026-09-19 | $-1.03 | $376,198 | 8 / 8 |
| 2026-09-20 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-21 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-22 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-23 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-24 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-25 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-26 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-27 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-28 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-29 | $-1.03 | $344,848 | 9 / 9 |
| 2026-09-30 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-01 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-02 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-03 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-04 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-05 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-06 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-07 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-08 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-09 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-10 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-11 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-12 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-13 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-14 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-15 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-16 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-17 | $-1.03 | $344,848 | 9 / 9 |
| 2026-10-18 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-19 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-20 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-21 | $-1.02 | $341,682 | 9 / 9 |
| 2026-10-22 | $-1.02 | $341,682 | 9 / 9 |
| 2026-10-23 | $-1.02 | $341,682 | 9 / 9 |
| 2026-10-24 | $-1.02 | $341,682 | 9 / 9 |
| 2026-10-25 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-26 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-27 | $-1.03 | $341,682 | 9 / 9 |
| 2026-10-28 | $-1.01 | $325,015 | 9 / 9 |
| 2026-10-29 | $-1.01 | $320,932 | 9 / 9 |
| 2026-10-30 | $-1.01 | $320,932 | 9 / 9 |
| 2026-10-31 | $-1.01 | $320,932 | 9 / 9 |
| 2026-11-01 | $-1.01 | $320,932 | 9 / 9 |
| 2026-11-02 | $-1.01 | $320,932 | 9 / 9 |
| 2026-11-03 | $-1.01 | $320,932 | 9 / 9 |
| 2026-11-04 | $-1.01 | $320,932 | 9 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.